The history and use of DNA-Encoded Libraries in drug discovery

DNA Encoded Libraries (DELs) have become an important and efficient approach for identifying novel chemical entities targeting a range of biomolecular architectures.
Barry Morgan led the development of the DEL platform at Praecis Pharmaceuticals, Boston, joining GSK to lead its continued investment in DEL screening after GSK bought Praecis in 2007. Since that time GSK has gone on to publish several novel chemical entities, now in late phase clinical development. What started as a theory from Sydney Brenner & Richard Lerner has truly come of age as a powerful drug-discovery approach.
Barry is now CSO at HitGen, who continue to build a strong DEL platform based in Chengdu, China.